

July 2022

## BCBSAL Prior Authorization Utilization Management

### Prior Authorization

Certain drugs require prior authorization to help promote safe, quality and affordable pharmacy care. Your doctor will need to submit a prior authorization request to Prime Therapeutics, which must be approved before you can continue to receive coverage for these drugs.

The Prior Authorization form that your physician will need to complete to request an approval can be found on the MyPrime website.

### Quantity Limit Consideration

Within the Prior Authorization program, Quantity Limit may apply. If there is medical reason why you need an amount that is greater than what is allowed, your physician can fill out a Quantity Limit prior authorization form for you and send it to Prime Therapeutics. This form can be found on the MyPrime.com website.

Utilization Management Program	Preferred Product(s)	Drug(s) in Program
<b>Acute Migraine Agents</b>		dihydroergotamine mesylate
		ELYXYB
		MIGRANAL
		REYVOW
		TRUDHESA
<b>Afrezza</b>		AFREZZA
<b>Amantadine ER</b>		GOCOVRI
		OSMOLEX ER
<b>Amifampridine</b>		FIRDAPSE
		RUZURGI
<b>Ampyra</b>		AMPYRA
		dalfampridine er
<b>Androgen/Anabolic Steroids</b>		ANADROL-50
		ANDRODERM
		ANDROGEL

This list may not be all inclusive. This list is subject to change. New-to-market products and variations of those products will not be added to the Utilization Management Program until they have been evaluated and approved by Prime Therapeutics. Please discuss with your health care provider before you switch any medications to ensure clinically appropriate use. This list is not intended to dictate to physicians how to practice medicine or intended to replace the judgment of your physician. Prime Therapeutics is not liable for any treatment administered or prescribed as a result of this Utilization Management information. Additional restrictions may apply. Neither this document, nor the successful adjudication of a pharmacy claim, is guarantee of payment. Please refer to your member guide for detailed information regarding your pharmacy benefits, including your benefit design, out-of-pocket costs, prior review and restricted access medication requests, and applicable exclusions. For more information, please contact your Prime Therapeutics representative. All brand names are the property of their respective owner". NetResults is a trademark of Prime Therapeutics LLC.

Utilization Management Program	Preferred Product(s)	Drug(s) in Program
		ANDROGEL PUMP
		danazol
		FORTESTA
		JATENZO
		METHITEST
		methyltestosterone
		NATESTO
		oxandrolone
		STRIANT
		TESTIM
		TESTOSTERONE
		TESTOSTERONE PUMP
		testosterone topical solution
		TLANDO
		VOGELXO
		VOGELXO PUMP
<b>Antifungal (Ciclopirox/Efinaconazole/Tavaborole)</b>		JUBLIA
		KERYDIN
		tavaborole
		ciclodan
		ciclopirox nail lacquer
<b>Arikayce</b>		ARIKAYCE
<b>ATTR Amyloidosis</b>		TEGSEDI
		VYNDAMAX
		VYNDAQEL
<b>Baclofen</b>		BACLOFEN
		FLEQSUVY
		OZOBAX
<b>Bempedoic Acid</b>		NEXLETOL
		NEXLIZET
<b>Biologic Immunomodulators</b>	<b>Preferred Products: Refer to Policy</b>	ACTEMRA
	<b>Preferred Products: Refer to Policy</b>	ACTEMRA ACTPEN
	<b>Preferred Products: Refer to Policy</b>	CIMZIA
	<b>Preferred Products: Refer to Policy</b>	CIMZIA STARTER KIT
	<b>Preferred Products: Refer to Policy</b>	COSENTYX
	<b>Preferred Products: Refer to Policy</b>	COSENTYX SENSOREADY PEN

This list may not be all inclusive. This list is subject to change. New-to-market products and variations of those products will not be added to the Utilization Management Program until they have been evaluated and approved by Prime Therapeutics. Please discuss with your health care provider before you switch any medications to ensure clinically appropriate use. This list is not intended to dictate to physicians how to practice medicine or intended to replace the judgment of your physician. Prime Therapeutics is not liable for any treatment administered or prescribed as a result of this Utilization Management information. Additional restrictions may apply. Neither this document, nor the successful adjudication of a pharmacy claim, is guarantee of payment. Please refer to your member guide for detailed information regarding your pharmacy benefits, including your benefit design, out-of-pocket costs, prior review and restricted access medication requests, and applicable exclusions. For more information, please contact your Prime Therapeutics representative. All brand names are the property of their respective owner". NetResults is a trademark of Prime Therapeutics LLC.

Utilization Management Program	Preferred Product(s)	Drug(s) in Program
	Preferred Products: Refer to Policy	ENBREL
	Preferred Products: Refer to Policy	ENBREL MINI
	Preferred Products: Refer to Policy	ENBREL SURECLICK
	Preferred Products: Refer to Policy	HUMIRA
	Preferred Products: Refer to Policy	HUMIRA PEDIATRIC CROHNS DISEASE STARTER PACK
	Preferred Products: Refer to Policy	HUMIRA PEN
	Preferred Products: Refer to Policy	HUMIRA PEN-CD/UC/HS STARTER
	Preferred Products: Refer to Policy	HUMIRA PEN-PEDIATRIC UC STARTER PACK
	Preferred Products: Refer to Policy	HUMIRA PEN-PS/UV STARTER
	Preferred Products: Refer to Policy	KEVZARA
	Preferred Products: Refer to Policy	KINERET
	Preferred Products: Refer to Policy	OLUMIANT
	Preferred Products: Refer to Policy	ORENCIA
	Preferred Products: Refer to Policy	ORENCIA CLICKJECT
	Preferred Products: Refer to Policy	RINVOQ
	Preferred Products: Refer to Policy	SILIQ
	Preferred Products: Refer to Policy	SIMPONI
	Preferred Products: Refer to Policy	SKYRIZI
	Preferred Products: Refer to Policy	SKYRIZI PEN
	Preferred Products: Refer to Policy	STELARA
	Preferred Products: Refer to Policy	TALTZ
	Preferred Products: Refer to Policy	TREMFYA
	Preferred Products: Refer to Policy	XELJANZ
	Preferred Products: Refer to Policy	XELJANZ XR
Bonjesta/Diclegis		BONJESTA
		DICLEGIS
		doxylamine succinate/pyridoxine hydrochloride
Buprenorphine Opioid Dependence		buprenorphine hcl
Cannabidiol		EPIDIOLEX
Carbaglu		CARBAGLU
		carglumic acid
CFTR		KALYDECO
		ORKAMBI
		SYMDEKO
		TRIKAFTA

This list may not be all inclusive. This list is subject to change. New-to-market products and variations of those products will not be added to the Utilization Management Program until they have been evaluated and approved by Prime Therapeutics. Please discuss with your health care provider before you switch any medications to ensure clinically appropriate use. This list is not intended to dictate to physicians how to practice medicine or intended to replace the judgment of your physician. Prime Therapeutics is not liable for any treatment administered or prescribed as a result of this Utilization Management information. Additional restrictions may apply. Neither this document, nor the successful adjudication of a pharmacy claim, is guarantee of payment. Please refer to your member guide for detailed information regarding your pharmacy benefits, including your benefit design, out-of-pocket costs, prior review and restricted access medication requests, and applicable exclusions. For more information, please contact your Prime Therapeutics representative. All brand names are the property of their respective owner". NetResults is a trademark of Prime Therapeutics LLC.

Utilization Management Program	Preferred Product(s)	Drug(s) in Program
<b>CGRP</b>	Preferred Products: Aimovig, Ajovy, Emgality, Nurtec, Ubrelvy	AIMOVIG
	Preferred Products: Aimovig, Ajovy, Emgality, Nurtec, Ubrelvy	AJOVY
	Preferred Products: Aimovig, Ajovy, Emgality, Nurtec, Ubrelvy	EMGALITY
	Preferred Products: Aimovig, Ajovy, Emgality, Nurtec, Ubrelvy	NURTEC
	Preferred Products: Aimovig, Ajovy, Emgality, Nurtec, Ubrelvy	QULIPTA
	Preferred Products: Aimovig, Ajovy, Emgality, Nurtec, Ubrelvy	UBRELVY
<b>Cholestasis Pruritus</b>		BYLVAY
		BYLVAY (PELLETS)
		LIVMARLI
<b>Constipation Agents</b>	Preferred Products: Symproic, Trulance, Movantik	AMITIZA
	Preferred Products: Symproic, Trulance, Movantik	IBSRELA
	Preferred Products: Symproic, Trulance, Movantik	LINZESS
	Preferred Products: Symproic, Trulance, Movantik	LUBIPROSTONE
	Preferred Products: Symproic, Trulance, Movantik	MOTEGRITY
	Preferred Products: Symproic, Trulance, Movantik	MOVANTIK
	Preferred Products: Symproic, Trulance, Movantik	RELISTOR
	Preferred Products: Symproic, Trulance, Movantik	SYMPROIC
	Preferred Products: Symproic, Trulance, Movantik	TRULANCE
	Preferred Products: Symproic, Trulance, Movantik	ZELNORM
<b>Corticotropin</b>		ACTHAR
		CORTROPHIN
<b>Dojolvi</b>		DOJOLVI
<b>Elagolix/Relugolix</b>		MYFEMBREE
		ORIAHNN
		ORILISSA
<b>Elmiron</b>		ELMIRON
<b>Emflaza</b>		EMFLAZA

This list may not be all inclusive. This list is subject to change. New-to-market products and variations of those products will not be added to the Utilization Management Program until they have been evaluated and approved by Prime Therapeutics. Please discuss with your health care provider before you switch any medications to ensure clinically appropriate use. This list is not intended to dictate to physicians how to practice medicine or intended to replace the judgment of your physician. Prime Therapeutics is not liable for any treatment administered or prescribed as a result of this Utilization Management information. Additional restrictions may apply. Neither this document, nor the successful adjudication of a pharmacy claim, is guarantee of payment. Please refer to your member guide for detailed information regarding your pharmacy benefits, including your benefit design, out-of-pocket costs, prior review and restricted access medication requests, and applicable exclusions. For more information, please contact your Prime Therapeutics representative. All brand names are the property of their respective owner". NetResults is a trademark of Prime Therapeutics LLC.

Utilization Management Program	Preferred Product(s)	Drug(s) in Program
Empaveli		EMPAVELI
Endari		ENDARI
Enspryng		ENSPRYNG
Eysuvis		EYSUVIS
Fintepla		FINTEPLA
Galafold		GALAFOLD
Gattex		GATTEX
Growth Hormone	Preferred Product: Norditropin	GENOTROPIN
	Preferred Product: Norditropin	GENOTROPIN MINIQUICK
	Preferred Product: Norditropin	HUMATROPE
	Preferred Product: Norditropin	HUMATROPE COMBO PACK
	Preferred Product: Norditropin	NORDITROPIN FLEXPLO
	Preferred Product: Norditropin	NUTROPIN AQ NUSPIN 10
	Preferred Product: Norditropin	NUTROPIN AQ NUSPIN 20
	Preferred Product: Norditropin	NUTROPIN AQ NUSPIN 5
	Preferred Product: Norditropin	OMNITROPE
	Preferred Product: Norditropin	SAIZEN
	Preferred Product: Norditropin	SAIZENPREP RECONSTITUTIONKIT
	Preferred Product: Norditropin	SEROSTIM
	Preferred Product: Norditropin	SKYTROFA
	Preferred Product: Norditropin	ZOMACTON
	Preferred Product: Norditropin	ZORBTIVE
HCN Channel Blocker		CORLANOR
Hemophilia Agents		SEVENFACT
		ADVATE
		ADYNOVATE
		AFSTYLA
		ALPHANATE
		ALPHANATE/VON WILLEBRAND FACTOR COMPLEX/HUMAN
		ALPHANINE SD
		ALPROLIX
		BENEFIX
		COAGADEX
		CORIFACT
		ELOCTATE
		ESPEROCT
		FEIBA
		HEMLIBRA

This list may not be all inclusive. This list is subject to change. New-to-market products and variations of those products will not be added to the Utilization Management Program until they have been evaluated and approved by Prime Therapeutics. Please discuss with your health care provider before you switch any medications to ensure clinically appropriate use. This list is not intended to dictate to physicians how to practice medicine or intended to replace the judgment of your physician. Prime Therapeutics is not liable for any treatment administered or prescribed as a result of this Utilization Management information. Additional restrictions may apply. Neither this document, nor the successful adjudication of a pharmacy claim, is guarantee of payment. Please refer to your member guide for detailed information regarding your pharmacy benefits, including your benefit design, out-of-pocket costs, prior review and restricted access medication requests, and applicable exclusions. For more information, please contact your Prime Therapeutics representative. All brand names are the property of their respective owner". NetResults is a trademark of Prime Therapeutics LLC.

Utilization Management Program	Preferred Product(s)	Drug(s) in Program
		HEMOFIL M
		HUMATE-P
		IDELVION
		IXINITY
		JIVI
		KOATE
		KOATE-DVI
		KOGENATE FS
		KOVALTRY
		MONONINE
		NOVOEIGHT
		NOVOSEVEN RT
		NUWIQ
		OBIZUR
		PROFILNINE
		REBINYN
		RECOMBIMATE
		RIXUBIS
		TRETTEN
		VONVENDI
		WILATE
		XYNTHA
		XYNTHA SOLOFUSE
<b>Hepatitis C Direct Acting Antivirals</b>	<b>Preferred Products: authorized generic sofosbuvir/velpatasvir, Epclusa, authorized generic ledipasvir/sofosbuvir, Harvoni, Mavyret, and Vosevi</b>	EPCLUSA
	<b>Preferred Products: authorized generic sofosbuvir/velpatasvir, Epclusa, authorized generic ledipasvir/sofosbuvir, Harvoni, Mavyret, and Vosevi</b>	HARVONI
	<b>Preferred Products: authorized generic sofosbuvir/velpatasvir, Epclusa, authorized generic ledipasvir/sofosbuvir, Harvoni, Mavyret, and Vosevi</b>	LEDIPASVIR/SOFOSBUVIR
	<b>Preferred Products: authorized generic sofosbuvir/velpatasvir, Epclusa, authorized generic ledipasvir/sofosbuvir, Harvoni, Mavyret, and Vosevi</b>	MAVYRET
	<b>Preferred Products: authorized generic sofosbuvir/velpatasvir, Epclusa,</b>	SOFOSBUVIR/VELPATASVIR

This list may not be all inclusive. This list is subject to change. New-to-market products and variations of those products will not be added to the Utilization Management Program until they have been evaluated and approved by Prime Therapeutics. Please discuss with your health care provider before you switch any medications to ensure clinically appropriate use. This list is not intended to dictate to physicians how to practice medicine or intended to replace the judgment of your physician. Prime Therapeutics is not liable for any treatment administered or prescribed as a result of this Utilization Management information. Additional restrictions may apply. Neither this document, nor the successful adjudication of a pharmacy claim, is guarantee of payment. Please refer to your member guide for detailed information regarding your pharmacy benefits, including your benefit design, out-of-pocket costs, prior review and restricted access medication requests, and applicable exclusions. For more information, please contact your Prime Therapeutics representative. All brand names are the property of their respective owner". NetResults is a trademark of Prime Therapeutics LLC.

Utilization Management Program	Preferred Product(s)	Drug(s) in Program
	authorized generic ledipasvir/sofosbuvir, Harvoni, Mavyret, and Vosevi	
	Preferred Products: authorized generic sofosbuvir/velpatasvir, Epclusa, authorized generic ledipasvir/sofosbuvir, Harvoni, Mavyret, and Vosevi	SOVALDI
	Preferred Products: authorized generic sofosbuvir/velpatasvir, Epclusa, authorized generic ledipasvir/sofosbuvir, Harvoni, Mavyret, and Vosevi	VIEKIRA PAK
	Preferred Products: authorized generic sofosbuvir/velpatasvir, Epclusa, authorized generic ledipasvir/sofosbuvir, Harvoni, Mavyret, and Vosevi	VOSEVI
	Preferred Products: authorized generic sofosbuvir/velpatasvir, Epclusa, authorized generic ledipasvir/sofosbuvir, Harvoni, Mavyret, and Vosevi	ZEPATIER
<b>Hereditary Angioedema</b>		BERINERT
		FIRAZYR
		HAEGARDA
		icatibant acetate
		KALBITOR
		ORLADEYO
		RUCONEST
		sajazir
		TAKHZYRO
<b>Hetlioz</b>		HETLIOZ
		HETLIOZ LQ
<b>HoFH Agents</b>		JUXTAPID
<b>HSDD</b>		ADDYI
		VYLEESI
<b>Hyperhidrosis</b>		QBREXZA
<b>Imcivree</b>		IMCIVREE
<b>Inhaled Antibiotics</b>		BETHKIS
		CAYSTON
		KITABIS PAK
		TOBI
		TOBI PODHALER
		TOBRAMYCIN

This list may not be all inclusive. This list is subject to change. New-to-market products and variations of those products will not be added to the Utilization Management Program until they have been evaluated and approved by Prime Therapeutics. Please discuss with your health care provider before you switch any medications to ensure clinically appropriate use. This list is not intended to dictate to physicians how to practice medicine or intended to replace the judgment of your physician. Prime Therapeutics is not liable for any treatment administered or prescribed as a result of this Utilization Management information. Additional restrictions may apply. Neither this document, nor the successful adjudication of a pharmacy claim, is guarantee of payment. Please refer to your member guide for detailed information regarding your pharmacy benefits, including your benefit design, out-of-pocket costs, prior review and restricted access medication requests, and applicable exclusions. For more information, please contact your Prime Therapeutics representative. All brand names are the property of their respective owner". NetResults is a trademark of Prime Therapeutics LLC.

Utilization Management Program	Preferred Product(s)	Drug(s) in Program
Interleukin (IL)-1 Inhibitors		ARCALYST
Interleukin (IL)-4 Inhibitors		DUPIXENT
Interleukin (IL)-5 Inhibitors		FASENRA PEN
		NUCALA
Interstitial Lung Disease		ESBRIET
		OFEV
Iron Chelation		deferiasirox
		deferiprone
		EXJADE
		FERRIPROX
		FERRIPROX TWICE-A-DAY
		JADENU
		JADENU SPRINKLE
Isturisa		ISTURISA
Ivermectin		ivermectin
		STROMECTOL
Jynarque		JYNARQUE
Kerendia		KERENDIA
Keveyis		KEVEYIS
Korlym		KORLYM
Long Acting Insulin	Preferred Products: Semglee, Insulin glargine-yfgn	LANTUS
	Preferred Products: Semglee, Insulin glargine-yfgn	LANTUS SOLOSTAR
Lucemyra		LUCEMYRA
Lupus		BENLYSTA
		LUPKYNIS
Lyrica CR		LYRICA CR
		pregabalin er
Myalept		MYALEPT
Natpara		NATPARA
Neurotrophic Keratitis		OXERVATE
Nocturia		NOC DURNA
Nothera		droxidopa
		NORTHERA
Ocaliva		OCALIVA

This list may not be all inclusive. This list is subject to change. New-to-market products and variations of those products will not be added to the Utilization Management Program until they have been evaluated and approved by Prime Therapeutics. Please discuss with your health care provider before you switch any medications to ensure clinically appropriate use. This list is not intended to dictate to physicians how to practice medicine or intended to replace the judgment of your physician. Prime Therapeutics is not liable for any treatment administered or prescribed as a result of this Utilization Management information. Additional restrictions may apply. Neither this document, nor the successful adjudication of a pharmacy claim, is guarantee of payment. Please refer to your member guide for detailed information regarding your pharmacy benefits, including your benefit design, out-of-pocket costs, prior review and restricted access medication requests, and applicable exclusions. For more information, please contact your Prime Therapeutics representative. All brand names are the property of their respective owner". NetResults is a trademark of Prime Therapeutics LLC.



Utilization Management Program	Preferred Product(s)	Drug(s) in Program
<b>Ophthalmic Immunomodulators</b>		CEQUA
		cyclosporine
		CYCLOSPORINE IN KLARITY
		RESTASIS
		RESTASIS MULTIDOSE
		VERKAZIA
		XIIDRA
<b>Opioids ER</b>		ARYMO ER
		BELBUCA
		buprenorphine
		BUTRANS
		CONZIP
		DURAGESIC
		fentanyl
		HYDROCODONE BITARTRATE ER
		hydromorphone hcl er
		hydromorphone hydrochloride er
		HYSINGLA ER
		KADIAN
		MORPHABOND ER
		MORPHINE SULFATE ER
		MS CONTIN
		NUCYNTA ER
		OXYCODONE HCL ER
		OXYCODONE HYDROCHLORIDE ER
		OXYCONTIN
		OXYMORPHONE HYDROCHLORIDE ER
		OXYMORPHONE HYDROCHLORIDEER
		TRAMADOL HCL ER
		XTAMPZA ER
		ZOHYDRO ER
<b>Opioids IR Duration Limit</b>		ACETAMINOPHEN/CAFFEINE/DIHYDROCODEINE
		acetaminophen/codeine
		acetaminophen/codeine phosphate
		APADAZ
		ascomp/codeine

This list may not be all inclusive. This list is subject to change. New-to-market products and variations of those products will not be added to the Utilization Management Program until they have been evaluated and approved by Prime Therapeutics. Please discuss with your health care provider before you switch any medications to ensure clinically appropriate use. This list is not intended to dictate to physicians how to practice medicine or intended to replace the judgment of your physician. Prime Therapeutics is not liable for any treatment administered or prescribed as a result of this Utilization Management information. Additional restrictions may apply. Neither this document, nor the successful adjudication of a pharmacy claim, is guarantee of payment. Please refer to your member guide for detailed information regarding your pharmacy benefits, including your benefit design, out-of-pocket costs, prior review and restricted access medication requests, and applicable exclusions. For more information, please contact your Prime Therapeutics representative. All brand names are the property of their respective owner". NetResults is a trademark of Prime Therapeutics LLC.

Utilization Management Program	Preferred Product(s)	Drug(s) in Program
		BENZHYDROCODONE/ACETAMINOPHEN
		butalbital/acetaminophen/caffeine/codeine
		butalbital/aspirin/caffeine/codeine
		butorphanol tartrate
		CODEINE SULFATE
		DILAUDID
		dvorah
		endocet
		FIORICET/CODEINE
		FIORINAL/CODEINE #3
		HYDROCODONE BITARTRATE/ACETAMINOPHEN
		hydrocodone/acetaminophen
		HYDROCODONE/IBUPROFEN
		hydromorphone hcl
		levorphanol tartrate
		lorcet
		lorcet hd
		lorcet plus
		LORTAB
		MEPERIDINE HCL
		METHADONE HCL
		methadone hydrochloride
		methadone hydrochloride intensol
		METHADOSE
		METHADOSE SUGAR-FREE
		MORPHINE SULFATE
		NALOCET
		NORCO
		NUCYNTA
		OPANA
		OXAYDO
		OXYCODONE AND ACETAMINOPHEN
		oxycodone hcl
		oxycodone hydrochloride

This list may not be all inclusive. This list is subject to change. New-to-market products and variations of those products will not be added to the Utilization Management Program until they have been evaluated and approved by Prime Therapeutics. Please discuss with your health care provider before you switch any medications to ensure clinically appropriate use. This list is not intended to dictate to physicians how to practice medicine or intended to replace the judgment of your physician. Prime Therapeutics is not liable for any treatment administered or prescribed as a result of this Utilization Management information. Additional restrictions may apply. Neither this document, nor the successful adjudication of a pharmacy claim, is guarantee of payment. Please refer to your member guide for detailed information regarding your pharmacy benefits, including your benefit design, out-of-pocket costs, prior review and restricted access medication requests, and applicable exclusions. For more information, please contact your Prime Therapeutics representative. All brand names are the property of their respective owner". NetResults is a trademark of Prime Therapeutics LLC.

Utilization Management Program	Preferred Product(s)	Drug(s) in Program
		OXYCODONE HYDROCHLORIDE/ACETAMINOPHEN
		OXYCODONE/ACETAMINOPHEN
		OXYCODONE/ASPIRIN
		OXYCODONE/IBUPROFEN
		oxymorphone hydrochloride
		pentazocine/naloxone hcl
		PERCOCET
		PRIMLEV
		PROLATE
		QDOLO
		ROXICODONE
		SEGLENTIS
		tramadol hcl
		TRAMADOL HYDROCHLORIDE
		tramadol hydrochloride/acetaminophen
		TREZIX
		TYLENOL/CODEINE #2
		TYLENOL/CODEINE #3
		ULTRACET
		ULTRAM
<b>Opzelura</b>		OPZELURA
<b>Oral PAH Agents</b>		ADCIRCA
		ADEMPAS
		alyq
		ambrisentan
		bosentan
		LETAIRIS
		OPSUMIT
		ORENITRAM
		REVATIO
		sildenafil citrate
		tadalafil
		TRACLEER
		TYVASO
		TYVASO REFILL
		TYVASO STARTER

This list may not be all inclusive. This list is subject to change. New-to-market products and variations of those products will not be added to the Utilization Management Program until they have been evaluated and approved by Prime Therapeutics. Please discuss with your health care provider before you switch any medications to ensure clinically appropriate use. This list is not intended to dictate to physicians how to practice medicine or intended to replace the judgment of your physician. Prime Therapeutics is not liable for any treatment administered or prescribed as a result of this Utilization Management information. Additional restrictions may apply. Neither this document, nor the successful adjudication of a pharmacy claim, is guarantee of payment. Please refer to your member guide for detailed information regarding your pharmacy benefits, including your benefit design, out-of-pocket costs, prior review and restricted access medication requests, and applicable exclusions. For more information, please contact your Prime Therapeutics representative. All brand names are the property of their respective owner". NetResults is a trademark of Prime Therapeutics LLC.

Utilization Management Program	Preferred Product(s)	Drug(s) in Program
		UPTRAVI
		VENTAVIS
Otezla		OTEZLA
Oxbryta		OXBRYTA
Oxybate		XYREM
		XYWAV
Parathyroid Hormone Analog for Osteoporosis	Preferred Products: Tymlos, Forteo	FORTEO
	Preferred Products: Tymlos, Forteo	TERIPARATIDE
	Preferred Products: Tymlos, Forteo	TYMLOS
PCSK-9 Inhibitors	Preferred Product: Repatha	PRALUENT
	Preferred Product: Repatha	REPATHA
	Preferred Product: Repatha	REPATHA PUSHTRONEX SYSTEM
	Preferred Product: Repatha	REPATHA SURECLICK
Peanut Allergy		PALFORZIA INITIAL DOSE ESCALATION
		PALFORZIA LEVEL 1
		PALFORZIA LEVEL 10
		PALFORZIA LEVEL 11 (MAINTENANCE)
		PALFORZIA LEVEL 11 (TITRATION)
		PALFORZIA LEVEL 2
		PALFORZIA LEVEL 3
		PALFORZIA LEVEL 4
		PALFORZIA LEVEL 5
		PALFORZIA LEVEL 6
		PALFORZIA LEVEL 7
		PALFORZIA LEVEL 8
		PALFORZIA LEVEL 9
Peginterferon		PEGASYS
		PEGASYS PROCLICK
		PEGINTRON
Phenylketonuria		KUVAN
		PALYNZIQ
		sapropterin dihydrochloride
Procysbi		PROCYSBI
Pseudobulbar Affect		NUDEXTA
Riluzole		EXSERVAN
		RILUTEK

This list may not be all inclusive. This list is subject to change. New-to-market products and variations of those products will not be added to the Utilization Management Program until they have been evaluated and approved by Prime Therapeutics. Please discuss with your health care provider before you switch any medications to ensure clinically appropriate use. This list is not intended to dictate to physicians how to practice medicine or intended to replace the judgment of your physician. Prime Therapeutics is not liable for any treatment administered or prescribed as a result of this Utilization Management information. Additional restrictions may apply. Neither this document, nor the successful adjudication of a pharmacy claim, is guarantee of payment. Please refer to your member guide for detailed information regarding your pharmacy benefits, including your benefit design, out-of-pocket costs, prior review and restricted access medication requests, and applicable exclusions. For more information, please contact your Prime Therapeutics representative. All brand names are the property of their respective owner". NetResults is a trademark of Prime Therapeutics LLC.

Utilization Management Program	Preferred Product(s)	Drug(s) in Program
		TIGLUTIK
<b>Risdiplam</b>		EVRYSDI
<b>SA Oncology</b>		abiraterone acetate
		AFINITOR
		AFINITOR DISPERZ
		ALECENSA
		ALUNBRIG
		AYVAKIT
		BALVERSA
	<b>Preferred Product: Peginterferon</b>	BESREMI
		bexarotene
	<b>Preferred Products: generic imatinib, Sprycel</b>	BOSULIF
		BRAFTOVI
		BRUKINSA
		CABOMETYX
		CALQUENCE
		capecitabine
		CAPRELSA
		COMETRIQ
		COPIKTRA
		COTELLIC
		DAURISMO
		ERIVEDGE
		ERLEADA
		erlotinib hydrochloride
		everolimus
		EXKIVITY
		FARYDAK
		FOTIVDA
		GAVRETO
		GILOTRIF
		GLEEVEC
		HYCAMTIN
		IBRANCE
		ICLUSIG
		IDHIFA
		imatinib mesylate
		IMBRUVICA

This list may not be all inclusive. This list is subject to change. New-to-market products and variations of those products will not be added to the Utilization Management Program until they have been evaluated and approved by Prime Therapeutics. Please discuss with your health care provider before you switch any medications to ensure clinically appropriate use. This list is not intended to dictate to physicians how to practice medicine or intended to replace the judgment of your physician. Prime Therapeutics is not liable for any treatment administered or prescribed as a result of this Utilization Management information. Additional restrictions may apply. Neither this document, nor the successful adjudication of a pharmacy claim, is guarantee of payment. Please refer to your member guide for detailed information regarding your pharmacy benefits, including your benefit design, out-of-pocket costs, prior review and restricted access medication requests, and applicable exclusions. For more information, please contact your Prime Therapeutics representative. All brand names are the property of their respective owner". NetResults is a trademark of Prime Therapeutics LLC.

Utilization Management Program	Preferred Product(s)	Drug(s) in Program
		INLYTA
		INQOVI
		INREBIC
		IRESSA
		JAKAFI
	<b>Preferred Products: Ibrance, Verzenio</b>	KISQALI
	<b>Preferred Products: Ibrance, Verzenio</b>	KISQALI FEMARA 200 DOSE
	<b>Preferred Products: Ibrance, Verzenio</b>	KISQALI FEMARA 400 DOSE
	<b>Preferred Products: Ibrance, Verzenio</b>	KISQALI FEMARA 600 DOSE
		KOSELUGO
		lapatinib ditosylate
		lenalidomide
		LENVIMA 10 MG DAILY DOSE
		LENVIMA 12MG DAILY DOSE
		LENVIMA 14 MG DAILY DOSE
		LENVIMA 18 MG DAILY DOSE
		LENVIMA 20 MG DAILY DOSE
		LENVIMA 24 MG DAILY DOSE
		LENVIMA 4 MG DAILY DOSE
		LENVIMA 8 MG DAILY DOSE
		LONSURF
		LORBRENA
		LUMAKRAS
		LYNPARZA
		LYSODREN
		MATULANE
		MEKINIST
		MEKTOVI
		NERLYNX
		NEXAVAR
		NINLARO
		NUBEQA
		ODOMZO
		ONUREG
		ORGOVYX
		PEMAZYRE
		PIQRAY 200MG DAILY DOSE
		PIQRAY 250MG DAILY DOSE
		PIQRAY 300MG DAILY DOSE

This list may not be all inclusive. This list is subject to change. New-to-market products and variations of those products will not be added to the Utilization Management Program until they have been evaluated and approved by Prime Therapeutics. Please discuss with your health care provider before you switch any medications to ensure clinically appropriate use. This list is not intended to dictate to physicians how to practice medicine or intended to replace the judgment of your physician. Prime Therapeutics is not liable for any treatment administered or prescribed as a result of this Utilization Management information. Additional restrictions may apply. Neither this document, nor the successful adjudication of a pharmacy claim, is guarantee of payment. Please refer to your member guide for detailed information regarding your pharmacy benefits, including your benefit design, out-of-pocket costs, prior review and restricted access medication requests, and applicable exclusions. For more information, please contact your Prime Therapeutics representative. All brand names are the property of their respective owner". NetResults is a trademark of Prime Therapeutics LLC.

Utilization Management Program	Preferred Product(s)	Drug(s) in Program
		POMALYST
		QINLOCK
		RETEVMO
		REVLIMID
		ROZLYTREK
		RUBRACA
		RYDAPT
	<b>Preferred Product: Iclusig</b>	SCSEMBLIX
		SPRYCEL
		STIVARGA
		sunitinib malate
		SUTENT
		TABRECTA
		TAFINLAR
		TAGRISSO
		TALZENNA
		TARCEVA
		TARGRETIN
	<b>Preferred Products: generic imatinib, Sprycel</b>	TASIGNA
		TAZVERIK
		TEMODAR
		temozolomide
		TEPMETKO
		THALOMID
		TIBSOVO
		tretinoin
		TRUSELTIQ
		TUKYSA
		TURALIO
		TYKERB
		UKONIQ
		VENCLEXTA
		VENCLEXTA STARTING PACK
		VERZENIO
		VITRAKVI
		VIZIMPRO
		VONJO
		VOTRIENT

This list may not be all inclusive. This list is subject to change. New-to-market products and variations of those products will not be added to the Utilization Management Program until they have been evaluated and approved by Prime Therapeutics. Please discuss with your health care provider before you switch any medications to ensure clinically appropriate use. This list is not intended to dictate to physicians how to practice medicine or intended to replace the judgment of your physician. Prime Therapeutics is not liable for any treatment administered or prescribed as a result of this Utilization Management information. Additional restrictions may apply. Neither this document, nor the successful adjudication of a pharmacy claim, is guarantee of payment. Please refer to your member guide for detailed information regarding your pharmacy benefits, including your benefit design, out-of-pocket costs, prior review and restricted access medication requests, and applicable exclusions. For more information, please contact your Prime Therapeutics representative. All brand names are the property of their respective owner". NetResults is a trademark of Prime Therapeutics LLC.

Utilization Management Program	Preferred Product(s)	Drug(s) in Program
		WELIREG
		XALKORI
		XELODA
		XOSPATA
		XPOVIO
		XPOVIO 100 MG ONCE WEEKLY
		XPOVIO 40 MG ONCE WEEKLY
		XPOVIO 40 MG TWICE WEEKLY
		XPOVIO 60 MG ONCE WEEKLY
		XPOVIO 60 MG TWICE WEEKLY
		XPOVIO 80 MG ONCE WEEKLY
		XPOVIO 80 MG TWICE WEEKLY
		XTANDI
		YONSA
		ZEJULA
		ZELBORAF
		ZOLINZA
		ZYDELIG
		ZYKADIA
		ZYTIGA
<b>Samsca</b>		SAMSCA
		TOLVAPTAN
<b>Signifor</b>		SIGNIFOR
<b>SSIA</b>		NUPLAZID
<b>Strensiq</b>		STRENSIQ
<b>Subcutaneous Immune Globulins</b>		CUTAUIG
		CUVITRU
		GAMMAGARD LIQUID
		GAMMAKED
		GAMUNEX-C
		HIZENTRA
		HYQVIA
		XEMBIFY
<b>Substrate Reduction Therapy</b>		CERDELGA
		miglustat
		ZAVESCA
<b>Sucraid</b>		SUCRAID

This list may not be all inclusive. This list is subject to change. New-to-market products and variations of those products will not be added to the Utilization Management Program until they have been evaluated and approved by Prime Therapeutics. Please discuss with your health care provider before you switch any medications to ensure clinically appropriate use. This list is not intended to dictate to physicians how to practice medicine or intended to replace the judgment of your physician. Prime Therapeutics is not liable for any treatment administered or prescribed as a result of this Utilization Management information. Additional restrictions may apply. Neither this document, nor the successful adjudication of a pharmacy claim, is guarantee of payment. Please refer to your member guide for detailed information regarding your pharmacy benefits, including your benefit design, out-of-pocket costs, prior review and restricted access medication requests, and applicable exclusions. For more information, please contact your Prime Therapeutics representative. All brand names are the property of their respective owner". NetResults is a trademark of Prime Therapeutics LLC.



Utilization Management Program	Preferred Product(s)	Drug(s) in Program
<b>Sucralfate Suspension</b>		CARAFATE
		sucralfate
<b>Sunosi</b>		SUNOSI
<b>Tavneos</b>		TAVNEOS
<b>Thrombopoietin Receptor Agonists</b>		DOPTelet
		MULPLETA
		PROMACTA
		TAVALISSE
<b>Topical AK Basal Cell Carcinoma Warts Agents</b>		ALDARA
		CARAC
		diclofenac sodium
		EFUDEX
		FLUOROPLEX
		FLUOROURACIL
		imiquimod
		imiquimod pump
		KLISYRI
		PICATO
		TOLAK
		ZYCLARA
		ZYCLARA PUMP
		FLUOROURACIL
<b>Topical Doxepin</b>		DOXEPIN HYDROCHLORIDE
		PRUDOXIN
		ZONALON
<b>Topical NSAID</b>		DICLOFENAC EPOLAMINE
		FLECTOR
		LICART
<b>Topiramate ER</b>		QUDEXY XR
		topiramate er
		TROKENDI XR
<b>Transmucosal Immediate Release Fentanyl</b>		ABSTRAL
		ACTIQ
		FENTANYL CITRATE
		fentanyl citrate oral transmucosal

This list may not be all inclusive. This list is subject to change. New-to-market products and variations of those products will not be added to the Utilization Management Program until they have been evaluated and approved by Prime Therapeutics. Please discuss with your health care provider before you switch any medications to ensure clinically appropriate use. This list is not intended to dictate to physicians how to practice medicine or intended to replace the judgment of your physician. Prime Therapeutics is not liable for any treatment administered or prescribed as a result of this Utilization Management information. Additional restrictions may apply. Neither this document, nor the successful adjudication of a pharmacy claim, is guarantee of payment. Please refer to your member guide for detailed information regarding your pharmacy benefits, including your benefit design, out-of-pocket costs, prior review and restricted access medication requests, and applicable exclusions. For more information, please contact your Prime Therapeutics representative. All brand names are the property of their respective owner". NetResults is a trademark of Prime Therapeutics LLC.

Utilization Management Program	Preferred Product(s)	Drug(s) in Program
		FENTORA
		LAZANDA
		SUBSYS
<b>Tyrvaya</b>		TYRVAYA
<b>Urea Cycle Disorders</b>		BUPHENYL
		RAVICTI
		sodium phenylbutyrate
<b>Verquvo</b>		VERQUVO
<b>VMAT2 Inhibitors</b>		AUSTEDO
		INGREZZA
		tetrabenazine
		XENAZINE
<b>Voxzogo</b>		VOXZOGO
<b>Wakix</b>		WAKIX
<b>Weight Loss Agents</b>		ADIPEX-P
		BENZPHETAMINE HCL
		CONTRAVE
		diethylpropion hcl
		DIETHYLPROPION HCL ER
		LOMAIRA
		phendimetrazine tartrate
		PHENDIMETRAZINE TARTRATE ER
		phentermine hcl
		phentermine hydrochloride
		QSYMIA
		SAXENDA
		WEGOVY
		XENICAL
<b>Xermelo</b>		XERMELO
<b>Xhance</b>		XHANCE
<b>Zeposia</b>	<b>Preferred Products for MS: Generic glatiramer, generic dimethyl fumarate; Preferred Products for UC: Humira, Rinvoq, Stelara, Xeljanz, Xeljanz XR</b>	ZEPOSIA
	<b>Preferred Products for MS: Generic glatiramer, generic dimethyl fumarate; Preferred Products for UC: Humira, Rinvoq, Stelara, Xeljanz, Xeljanz XR</b>	ZEPOSIA 7-DAY STARTER PACK
	<b>Preferred Products for MS: Generic glatiramer, generic dimethyl fumarate;</b>	ZEPOSIA STARTER KIT

This list may not be all inclusive. This list is subject to change. New-to-market products and variations of those products will not be added to the Utilization Management Program until they have been evaluated and approved by Prime Therapeutics. Please discuss with your health care provider before you switch any medications to ensure clinically appropriate use. This list is not intended to dictate to physicians how to practice medicine or intended to replace the judgment of your physician. Prime Therapeutics is not liable for any treatment administered or prescribed as a result of this Utilization Management information. Additional restrictions may apply. Neither this document, nor the successful adjudication of a pharmacy claim, is guarantee of payment. Please refer to your member guide for detailed information regarding your pharmacy benefits, including your benefit design, out-of-pocket costs, prior review and restricted access medication requests, and applicable exclusions. For more information, please contact your Prime Therapeutics representative. All brand names are the property of their respective owner". NetResults is a trademark of Prime Therapeutics LLC.

Utilization Management Program	Preferred Product(s)	Drug(s) in Program
	Preferred Products for UC: Humira, Rinvoq, Stelara, Xeljanz, Xeljanz XR	
Zokinvy		ZOKINVY

This list may not be all inclusive. This list is subject to change. New-to-market products and variations of those products will not be added to the Utilization Management Program until they have been evaluated and approved by Prime Therapeutics. Please discuss with your health care provider before you switch any medications to ensure clinically appropriate use. This list is not intended to dictate to physicians how to practice medicine or intended to replace the judgment of your physician. Prime Therapeutics is not liable for any treatment administered or prescribed as a result of this Utilization Management information. Additional restrictions may apply. Neither this document, nor the successful adjudication of a pharmacy claim, is guarantee of payment. Please refer to your member guide for detailed information regarding your pharmacy benefits, including your benefit design, out-of-pocket costs, prior review and restricted access medication requests, and applicable exclusions. For more information, please contact your Prime Therapeutics representative. All brand names are the property of their respective owner". NetResults is a trademark of Prime Therapeutics LLC.